BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Por Cabanillas, M. E., Patel, A., Danysh, B. P., Dadu, R., Kopetz, S., Falchook, G.
Publicado no Horm Cancer (2014)

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer(†)

Por Falchook, G. S., Moulder, S. L., Wheler, J. J., Jiang, Y., Bastida, C. C., Kurzrock, R.
Publicado em 2013

Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies

Por Falchook, G. S., Duvic, M., Hong, D. S., Wheler, J., Naing, A., Lim, J., Kurzrock, R.
Publicado em 2011

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

Por Wheler, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Moulder, S., Stephen, B., Wen, S., Kurzrock, R.
Publicado em 2012

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Por Falchook, G.S., Trent, J.C., Heinrich, M.C, Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R.
Publicado em 2013

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

Por Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E., Hosing, C., Verstovsek, S., Pro, B.
Publicado em 2009

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

Por Wheler, J. J., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Piha-Paul, S. A., Chen, S. S., Fu, S., Stephen, B., Fok, J. Y., Janku, F., Kurzrock, R.
Publicado em 2013

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials

Por Said, R., Banchs, J., Wheler, J., Hess, K. R., Falchook, G., Fu, S., Naing, A., Hong, D., Piha-Paul, S., Ye, Y., Yeh, E., Wolff, R. A., Tsimberidou, A. M.
Publicado em 2014

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes

Por Henary, H., Hong, D. S., Falchook, G. S., Tsimberidou, A., George, G. C., Wen, S., Wheler, J., Fu, S., Naing, A., Piha-Paul, S., Janku, F., Kim, K. B., Hwu, P., Kurzrock, R.
Publicado em 2013

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Por Naing, A., Veasey-Rodrigues, H., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., Aaron, J., Ewer, M. S., Kurzrock, R.
Publicado em 2012

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

Por Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.
Publicado em 2012

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Por Liu, X., George, G. C., Tsimberidou, A. M., Naing, A., Wheler, J. J., Kopetz, S., Fu, S., Piha-Paul, S. A., Eng, C., Falchook, G. S., Janku, F., Garrett, C., Karp, D., Kurzrock, R., Zinner, R., Raghav, K., Subbiah, V., Hess, K., Meric-Bernstam, F., Hong, D. S., Overman, M. J.
Publicado no BMC Cancer (2015)